C.M. Bidwell & Associates’s Adicet Bio ACET Stock Holding History

C.M. Bidwell & Associates’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-490	Closed	-$70K	–	511
2022 Q4	$70K	Buy	+490	New	+$122K	0.06%	262

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

C.M. Bidwell & Associates's ACET Position: Q1 2023 in Review

C.M. Bidwell & Associates sold out of Adicet Bio (ACET) in Q1 2023, closing a stake of 490 shares — an estimated $70K sold.

C.M. Bidwell & Associates first reported a position in ACET in Q4 2022 and held it in 1 quarter. The position peaked at $70K in Q4 2022. 107 funds tracked by Wall St. Rank hold ACET as of Q1 2023.

C.M. Bidwell & Associates reported no remaining Adicet Bio position as of Q1 2023 after selling out during the quarter.
C.M. Bidwell & Associates sold 490 Adicet Bio shares in Q1 2023, an estimated $70K.
C.M. Bidwell & Associates first reported a position in Adicet Bio in Q4 2022 and held it in 1 quarter.
C.M. Bidwell & Associates's Adicet Bio position peaked at $70K in Q4 2022.
107 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2023.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2023, filed 12 May 2023.